We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Molecular evidence for selinexor as a treatment for Merkel cell polyomavirus (MCPyV)‐positive Merkel cell carcinoma.
- Authors
Bartley, Brooke R.; Simonette, Rebecca A.; Rady, Peter L.; Doan, Hung Q.; Tyring, Stephen K.
- Abstract
MS-1 and MKL-1 cell lines with increasing selinexor concentrations results in downregulation of all evaluated MCC-specific tumor proteins (Fig. Dose-dependent downregulation of Merkel cell carcinoma tumor markers utilizing selinexor gl MCC tumor proteins - HMGB1, ATOH1, SOX2, Islet-1, LSD1, and survivin - are critical for MCC carcinogenesis. Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine carcinoma etiologically linked to clonal integration of Merkel cell polyomavirus (MCPyV) (virus-positive MCC) and UV radiation (virus-negative MCC).[1] The prevalence of MCPyV-positive MCC varies worldwide, with one study showing that 69% of MCC tumors were virus positive in the United States whereas only 24% of tumors were virus positive in Australia.[2] Although surgery and radiation can be effective for local MCC, more effective treatment is needed for systemic MCC.
- Subjects
MERKEL cells; POLYOMAVIRUSES; TUMOR proteins; GLYCERALDEHYDEPHOSPHATE dehydrogenase; MERKEL cell carcinoma
- Publication
International Journal of Dermatology, 2023, Vol 62, Issue 2, pe68
- ISSN
0011-9059
- Publication type
Article
- DOI
10.1111/ijd.16057